scispace - formally typeset
K

Ka Wai Tam

Researcher at Taipei Medical University

Publications -  105
Citations -  2407

Ka Wai Tam is an academic researcher from Taipei Medical University. The author has contributed to research in topics: Randomized controlled trial & Medicine. The author has an hindex of 24, co-authored 79 publications receiving 1883 citations. Previous affiliations of Ka Wai Tam include Taipei Medical University Hospital.

Papers
More filters
Journal ArticleDOI

Effects of manual lymphatic drainage on breast cancer-related lymphedema: A systematic review and meta-analysis of randomized controlled trials

TL;DR: The current evidence from RCTs does not support the use of MLD in preventing or treating lymphedema, and clinical and statistical inconsistencies between the various studies confounded the evaluation of the effect ofMLD on breast-cancer-related lyMPhedema.
Journal ArticleDOI

Regional citrate versus heparin anticoagulation for continuous renal replacement therapy: a meta-analysis of randomized controlled trials

TL;DR: Citrate anticoagulation decreased the risk of bleeding with no significant increase in the incidence of metabolic alkalosis, and Hypocalcemia was more common in patients receiving citrate, although no clinical adverse event was reported in the included studies.
Journal ArticleDOI

Outcomes of staple fixation of mesh versus nonfixation in laparoscopic total extraperitoneal inguinal repair: a meta-analysis of randomized controlled trials

TL;DR: Elimination of tack fixation of mesh in TEP inguinal hernia repair is associated with decreased operative cost and significantly reduce operative time and in-hospital stay, but no difference in the risk of hernia recurrence, complications, and postoperative pain.
Journal ArticleDOI

Increased expression of enolase α in human breast cancer confers tamoxifen resistance in human breast cancer cells

TL;DR: The data presented here demonstrate that those patients whose tumors highly expressed ENO-1 had a poor prognosis with greater tumor size, poor nodal status, and a shorter disease-free interval, and suggest that downregulation of ENo-1 could be utilized as a novel pharmacological approach for overcoming 4-OHT resistance in breast cancer therapy.